HPRL
MCID: HYP020
MIFTS: 64

Hyperprolactinemia (HPRL)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hyperprolactinemia

MalaCards integrated aliases for Hyperprolactinemia:

Name: Hyperprolactinemia 56 12 74 73 36 29 54 6 43 15 17 71
Chiari-Frommel Syndrome 12 74 52 43 71
Hyperprolactinaemia 12 32
Hprl 56 73
Familial Isolated Prolactin Receptor Deficiency 58
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 58
Hyperprolactinemia, 39

Characteristics:

Orphanet epidemiological data:

58
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

OMIM:

56
Inheritance:
autosomal recessive
autosomal dominant


HPO:

31

Classifications:

Orphanet: 58  
Rare infertility disorders
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:12700
OMIM 56 615555
KEGG 36 H01388
NCIt 49 C113168
SNOMED-CT 67 237662005 85039006
ICD10 32 E22.1
ICD10 via Orphanet 33 E22.1
Orphanet 58 ORPHA397685
MedGen 41 C0020514
UMLS 71 C0008043 C0020514

Summaries for Hyperprolactinemia

OMIM : 56 Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiologic hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, primarily prolactinomas (see 102200). However, 10 to 60% of patients with hyperprolactinemia who undergo MRI have normal findings (summary by Newey et al., 2013). Patients with hyperprolactinemia may also experience agalactia (Kobayashi et al., 2018). (615555)

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to galactorrhea and mccune-albright syndrome. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and JAK-STAT signaling pathway. The drugs Orlistat and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, ovary and bone, and related phenotypes are galactorrhea and oligomenorrhea

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

KEGG : 36 Hyperprolactinemia unrelated to pregnancy is a disorder characterized by excess production of prolactin (PRL) and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiological hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, which are usually identifiable by means of magnetic resonance imaging (MRI). Some cases are due to prolactinomas and lesions in the pituitary stalk. A human germline PRLR mutation has been found in familial isolated hyperprolactinemia.

UniProtKB/Swiss-Prot : 73 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Wikipedia : 74 Hyperprolactinaemia is the presence of abnormally high levels of prolactin in the blood. Normal levels... more...

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 585, show less)
# Related Disease Score Top Affiliating Genes
1 galactorrhea 33.3 PRLR PRL IGF1 DRD2
2 mccune-albright syndrome 32.3 SST PTHLH PRL IGF1 GNAS GH1
3 hypogonadotropic hypogonadism 32.3 SHBG PRL INS GNRH1
4 pituitary tumors 31.1 SST PRL POMC IGF1 GNAS GH1
5 precocious puberty 31.0 GNRH1 GNAS GH1
6 diabetes insipidus 30.8 PRL POMC INS GH1
7 thyroiditis 30.7 TRH PRL INS
8 hypogonadism 30.7 SHBG PRL INS IGF1 GNRH1
9 amenorrhea 30.7 TRH SHBG PRL POMC INS IGF1
10 non-functioning pituitary adenoma 30.6 SST GH1
11 gynecomastia 30.6 SHBG PRL POMC GNRH1 DRD2
12 gigantism 30.5 PRL GHRH GH1
13 adenoma 30.5 TRH SST PRL POMC IGF1 GNAS
14 chromophobe adenoma 30.5 TRH PRLR PRL POMC GH1
15 central precocious puberty 30.4 IGF1 GNRH1 GH1
16 abducens nerve disease 30.4 PRL POMC
17 tsh producing pituitary tumor 30.4 SST PRL GH1
18 intracranial hypertension, idiopathic 30.4 POMC IGF1 GH1
19 impotence 30.3 VIP SHBG PRL POMC INS GNRH1
20 tic disorder 30.3 HTR2A DRD4 DRD2
21 sheehan syndrome 30.3 PRL POMC INS IGF1
22 lymphocytic hypophysitis 30.3 POMC GH1
23 anovulation 30.3 SHBG PRL INS IGF1 GNRH1 DRD2
24 craniopharyngioma 30.3 TRH PRL INS IGF1 GNRH1 GH1
25 secondary adrenal insufficiency 30.3 INS IGF1
26 premenstrual tension 30.3 SHBG POMC GNRH1
27 bone resorption disease 30.3 PTHLH INS IGF1
28 chiasmal syndrome 30.2 SST POMC
29 acth deficiency, isolated 30.2 TRH PRL POMC
30 ovarian cyst 30.2 PRL GNRH1 GNAS
31 empty sella syndrome 30.2 TRH PRL POMC INS IGF1 GNRH1
32 meningioma, familial 30.2 SST PRL POMC IGF1
33 infertility 30.2 SHBG PRLR PRL H19 GNRH1
34 psychotic disorder 30.1 PRL HTR2C HTR2A DRD4 DRD2
35 leydig cell tumor 30.1 PTHLH GNRH1 GNAS
36 acth-secreting pituitary adenoma 30.1 SST PRL POMC
37 adrenal adenoma 30.0 POMC INS GNAS
38 migraine without aura 30.0 PRL DRD4 DRD2
39 parathyroid adenoma 30.0 PTHLH IGF1 GNAS
40 fasting hypoglycemia 30.0 POMC IGF1
41 polycystic ovary syndrome 30.0 SHBG PRL POMC INS IGF1 GNRH1
42 tuberous sclerosis 30.0 SST POMC INS IGF1
43 pituitary adenoma 1, multiple types 30.0 SST PRL IGF1 GH1
44 fibromyalgia 29.9 PRL POMC IGF1 HTR2A DRD2
45 estrogen excess 29.8 SHBG PRL GNRH1
46 gastroparesis 29.8 SST PRL DRD4 DRD2
47 glucose intolerance 29.8 SHBG POMC INS IGF1 GH1
48 pituitary adenoma, prolactin-secreting 29.8 TRH SST PTHLH PRL POMC IGF1
49 schizophreniform disorder 29.8 PRL HTR2A DRD4 DRD2
50 hypoglycemia 29.8 SST PRL POMC INS IGF1 GHRH
51 hypothalamic disease 29.8 TRH PRL POMC INS GNRH1 GHRH
52 ovarian disease 29.7 SHBG PRL POMC INS IGF1 GNRH1
53 pituitary hormone deficiency, combined, 2 29.7 TRH PRL POMC IGF1 GHRH GH1
54 constipation 29.7 VIP SST INS HTR2A GAL
55 serotonin syndrome 29.7 SST HTR2A GHRH
56 schizoaffective disorder 29.7 SST PRL INS HTR2A DRD4 DRD2
57 ileus 29.7 VIP SST POMC INS
58 isolated growth hormone deficiency 29.7 POMC IGF1 GHRH GH1
59 hyperinsulinism 29.7 SST SHBG INS IGF1 GNRH1 GH1
60 primary hyperparathyroidism 29.7 PTHLH PRL POMC INS IGF1
61 ovarian hyperstimulation syndrome 29.7 SHBG INS GNRH1
62 leptin deficiency or dysfunction 29.7 TRH POMC INS IGF1 GNRH1
63 mental depression 29.7 POMC HTR2C HTR2A DRD4 DRD2
64 alcohol use disorder 29.7 HTR2C HTR2A GAL DRD2
65 hyperandrogenism 29.7 SHBG PRL POMC INS IGF1 GNRH1
66 mood disorder 29.6 POMC HTR2C HTR2A DRD4 DRD2
67 alcohol dependence 29.6 PRL POMC HTR2C HTR2A DRD4 DRD2
68 breast disease 29.6 SHBG PRLR PRL POMC IGF1
69 androgenic alopecia 29.6 SHBG PRL INS IGF1
70 irritable bowel syndrome 29.6 VIP SST POMC HTR2A
71 graves disease 1 29.6 TRH SHBG POMC INS
72 bipolar i disorder 29.6 HTR2C HTR2A DRD4 DRD2
73 sleep apnea 29.5 INS IGF1 HTR2C HTR2A
74 growth hormone secreting pituitary adenoma 29.5 SST PRL POMC IGF1 GNAS GHRH
75 leiomyoma, uterine 29.5 SHBG IGF1 GNRH1
76 congenital hypothyroidism 29.5 SHBG PRL IGF1 GNAS GH1
77 fibrous dysplasia 29.4 SST PTHLH PRL IGF1 GNAS GHRH
78 eating disorder 29.4 POMC HTR2C HTR2A GH1 DRD2
79 acanthosis nigricans 29.4 SHBG PRL INS IGF1 GH1
80 delusional disorder 29.4 PRL HTR2C HTR2A DRD4 DRD2
81 pituitary apoplexy 29.4 TRH SST PRL POMC INS IGF1
82 lipoid congenital adrenal hyperplasia 29.4 SHBG PRL POMC INS GNRH1
83 autism spectrum disorder 29.3 POMC IGF1 HTR2C HTR2A DRD4 DRD2
84 pituitary-dependent cushing's disease 29.3 TRH SST PRL POMC GHRH GH1
85 insulin-like growth factor i 29.3 SHBG PRL INS IGF1 GHRH GH1
86 post-traumatic stress disorder 29.3 POMC HTR2A DRD2
87 substance abuse 29.3 PRL POMC INS HTR2A DRD4 DRD2
88 disease of mental health 29.3 POMC INS HTR2C HTR2A DRD4 DRD2
89 goiter 29.3 TRH SST SHBG PRL INS IGF1
90 multiple endocrine neoplasia, type i 29.3 VIP SST PRL POMC INS GNAS
91 hypothyroidism 29.3 TRH SST SHBG PRL POMC INS
92 hyperthyroidism 29.2 TRH SST SHBG PRL POMC INS
93 hypopituitarism 29.2 TRH SHBG PRL POMC INS IGF1
94 conn's syndrome 29.2 TRH SST PRL POMC IGF1 GNRH1
95 septooptic dysplasia 29.1 TRH PRL POMC IGF1 GNRH1 GHRH
96 personality disorder 29.1 SST PRL HTR2C HTR2A DRD4 DRD2
97 migraine with or without aura 1 29.1 VIP PRL POMC INS HTR2C HTR2A
98 autism 29.0 PRL POMC IGF1 HTR2C HTR2A DRD4
99 sexual disorder 29.0 SHBG PRL POMC INS IGF1 HTR2C
100 pituitary adenoma 29.0 TRH SST PRL POMC IGF1 H19
101 schizophrenia 29.0 SST PRL POMC INS IGF1 HTR2C
102 osteoporosis 28.9 SHBG PTHLH PRL INS IGF1 GNRH1
103 bipolar disorder 28.9 SST SHBG PRL IGF1 HTR2C HTR2A
104 diabetes mellitus 28.8 SST SHBG PRL POMC INS IGF1
105 functioning pituitary adenoma 28.8 TRH SST PRLR PRL POMC IGF1
106 major depressive disorder 28.8 SST PRL POMC HTR2C HTR2A GAL
107 anxiety 28.7 PRL POMC INS HTR2C HTR2A GAL
108 thyroid gland disease 28.7 TRH SST SHBG PRL POMC INS
109 pituitary gland disease 28.7 TRH SST PRLR PRL POMC INS
110 hypertension, essential 28.2 VIP SST SHBG PRL POMC INS
111 panic disorder 28.1 TRH PRL POMC HTR2C HTR2A GHRH
112 acromegaly 28.0 VIP TRH SST SHBG PRLR PRL
113 prader-willi syndrome 28.0 TRH PRL POMC INS IGF1 HTR2C
114 diabetes mellitus, noninsulin-dependent 27.9 SST SHBG POMC INS IGF1 HTR2A
115 anorexia nervosa 27.5 SHBG PRL POMC INS IGF1 HTR2C
116 body mass index quantitative trait locus 11 25.7 TRH SHBG PRL POMC INS IGF1
117 galactorrhoea-hyperprolactinaemia 11.8
118 generalized resistance to thyroid hormone 10.6 TRH PRL
119 lipid-rich breast carcinoma 10.6 PRLR PRL
120 acth-independent macronodular adrenal hyperplasia 1 10.5 POMC GNAS
121 acth-dependent cushing syndrome 10.5 PRL POMC
122 tuberculum sellae meningioma 10.5 PRL POMC
123 sella turcica neoplasm 10.5 PRL POMC
124 fibrous dysplasia/mccune-albright syndrome 10.5 PRL GNAS GH1
125 breast adenoma 10.5 PRLR PRL
126 bronchial adenomas/carcinoids childhood 10.5 SST POMC
127 mammographic density 10.5 PRL IGF1
128 protein-deficiency anemia 10.5 INS GH1
129 hypothyroidism, congenital, nongoitrous, 4 10.5 PRL POMC GH1
130 prolactin producing pituitary tumor 10.5 PRL POMC DRD2
131 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.4 INS IGF1
132 infant gynecomastia 10.4
133 traumatic brain injury 10.4 IGF1 GH1 DRD2
134 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 10.4 GHRH GH1
135 acth-independent macronodular adrenal hyperplasia 10.4 POMC GNRH1 GNAS
136 aromatase deficiency 10.4 INS GNRH1 GH1
137 central nervous system benign neoplasm 10.4 PRL POMC IGF1
138 nelson syndrome 10.4 SST PRL POMC
139 rectum neuroendocrine neoplasm 10.4 VIP SST
140 trichotillomania 10.4 PRL DRD4 DRD2
141 tardive dyskinesia 10.4 HTR2A DRD2
142 adermatoglyphia 10.4 INS IGF1 GH1
143 acute endometritis 10.4 GNRH1 GAL
144 kleptomania 10.4 DRD4 DRD2
145 functionless pituitary adenoma 10.4 SST POMC IGF1
146 acrokeratoderma, hereditary papulotranslucent 10.4 VIP PRL
147 adenohypophysitis 10.4 TRH PRL POMC GH1
148 polyp of corpus uteri 10.4 PRL GNRH1
149 persistent fetal circulation syndrome 10.3 POMC INS IGF1
150 pancreatic somatostatinoma 10.3 VIP SST
151 duodenal somatostatinoma 10.3 SST INS
152 adult syndrome 10.3 POMC INS IGF1
153 melancholia 10.3 PRL POMC HTR2A
154 spinocerebellar degeneration 10.3 SST PRL
155 van maldergem syndrome 1 10.3 PRL POMC GNRH1 GH1
156 glucagonoma 10.3 VIP SST
157 colon neuroendocrine neoplasm 10.3 VIP PTHLH POMC
158 parathyroid gland disease 10.3 PTHLH INS IGF1
159 inhibited female orgasm 10.3 SHBG PRL
160 mineral metabolism disease 10.3 PTHLH POMC INS
161 phobic disorder 10.3 POMC HTR2A DRD2
162 gangliocytoma 10.3 PRL POMC GHRH
163 drug psychosis 10.3 HTR2A DRD4 DRD2
164 hypoparathyroidism 10.3 PTHLH INS IGF1 GNAS
165 drug-induced mental disorder 10.3 HTR2A DRD4 DRD2
166 substance-induced psychosis 10.3 HTR2A DRD4 DRD2
167 cyclothymic disorder 10.3 HTR2A DRD4 DRD2
168 autonomic nervous system benign neoplasm 10.3 VIP SST POMC
169 peripheral nervous system benign neoplasm 10.3 VIP SST POMC
170 autoimmune disease 10.3
171 conduct disorder 10.3 POMC DRD4 DRD2
172 isolated growth hormone deficiency, type ii 10.3 IGF1 GHRH GH1
173 systemic lupus erythematosus 10.3
174 pseudopseudohypoparathyroidism 10.3 PTHLH GNAS GHRH
175 apnea, obstructive sleep 10.3 INS IGF1 HTR2A
176 functional gastric disease 10.3 VIP SST INS
177 impulse control disorder 10.3 HTR2A DRD4 DRD2
178 pathological gambling 10.3 HTR2A DRD4 DRD2
179 pyometritis 10.3 PRL GNRH1
180 chondrodysplasia, blomstrand type 10.3 PTHLH GNAS GHRH
181 hypothalamic obesity 10.3 INS IGF1 GHRH
182 ahumada del castillo syndrome 10.2
183 potter's syndrome 10.2 INS IGF1
184 lupus erythematosus 10.2
185 microvascular complications of diabetes 1 10.2 SST INS IGF1
186 pseudohypoparathyroidism, type ib 10.2 PTHLH GNAS GHRH
187 bone remodeling disease 10.2 PTHLH INS IGF1
188 kidney disease 10.2
189 postgastrectomy syndrome 10.2 SST INS
190 carcinoid syndrome 10.2 SST IGF1 GHRH
191 opiate dependence 10.2 POMC IGF1 DRD4 DRD2
192 nerve compression syndrome 10.2 INS IGF1 GHRH
193 intermittent explosive disorder 10.2 HTR2C HTR2A DRD2
194 pseudohypoparathyroidism 10.2 TRH PTHLH PRL IGF1 GNAS
195 normal pressure hydrocephalus 10.2 VIP SST IGF1
196 ectopic cushing syndrome 10.2 SST POMC
197 restless legs syndrome 10.2 PRL POMC DRD4 DRD2
198 amenorrhea-galactorrhea syndrome 10.2
199 mastitis 10.2
200 hypochondriasis 10.2 POMC HTR2C HTR2A
201 pelvic varices 10.2 SHBG PRL GNRH1
202 diabetes insipidus, neurohypophyseal 10.2 TRH PRL POMC IGF1 GNRH1
203 antisocial personality disorder 10.2 PRL HTR2A DRD4 DRD2
204 bruxism 10.2 HTR2C HTR2A DRD2
205 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
206 short bowel syndrome 10.2 VIP SST IGF1 GH1
207 pancreatic cholera 10.2 VIP SST GHRH
208 endocrine pancreas disease 10.2 VIP SST GHRH
209 varicocele 10.2 SHBG PRL GNRH1
210 aromatase excess syndrome 10.1 SHBG POMC IGF1
211 speech and communication disorders 10.1 POMC INS DRD4 DRD2
212 male infertility 10.1
213 oligospermia 10.1
214 multiple endocrine neoplasia 10.1
215 depression 10.1
216 skin tag 10.1 SHBG INS IGF1
217 pancreatic cystadenoma 10.1 VIP SST POMC INS
218 glucose metabolism disease 10.1 SST POMC INS IGF1
219 gastrinoma 10.1 VIP SST POMC INS
220 oculogyric crisis 10.1 DRD4 DRD2
221 hyperglycemia 10.1 SST INS IGF1 GH1
222 major affective disorder 8 10.1
223 major affective disorder 9 10.1
224 granulomatous mastitis 10.1
225 generalized anxiety disorder 10.1 HTR2C HTR2A DRD2
226 borderline personality disorder 10.1 PRL HTR2C HTR2A DRD2
227 status epilepticus 10.1 SST GAL DRD2
228 cholera 10.1 VIP INS GNAS GAL
229 hydrocephalus 10.1 VIP SST PRL IGF1
230 neurofibromatosis, type ii 10.1
231 breast cancer 10.1
232 endometriosis 10.1
233 liver cirrhosis 10.1
234 uterine benign neoplasm 10.1 SHBG PRL IGF1 GNRH1
235 reproductive organ benign neoplasm 10.1 SHBG PRL IGF1 GNRH1
236 cell type benign neoplasm 10.1 SST PRL POMC INS IGF1
237 endocrine system disease 10.1 SST PRL POMC INS IGF1
238 multiple sclerosis 10.0
239 heart valve disease 10.0
240 uremia 10.0
241 marasmus 10.0 SHBG INS IGF1 GH1
242 chronic fatigue syndrome 10.0 PRL POMC INS IGF1 HTR2A
243 hair disease 10.0 SHBG POMC INS
244 vipoma 10.0 VIP SST GHRH GH1
245 lingual-facial-buccal dyskinesia 10.0 HTR2C HTR2A DRD4 DRD2
246 pigmentation disease 10.0 SHBG POMC INS IGF1
247 hyperostosis frontalis interna 10.0
248 hyperostosis 10.0
249 stuttering 10.0 SST SHBG GNRH1 DRD2
250 pituitary carcinoma 10.0 SST PRL POMC GNAS GHRH
251 hashimoto thyroiditis 10.0
252 meningioma, radiation-induced 10.0
253 spinal meningioma 10.0
254 azoospermia 10.0
255 lipid metabolism disorder 10.0
256 secretory meningioma 10.0
257 lymphoplasmacyte-rich meningioma 10.0
258 end stage renal disease 10.0
259 central congenital hypothyroidism 10.0
260 growth hormone deficiency 10.0
261 pure autonomic failure 10.0
262 aneurysm 10.0
263 encephalopathy 10.0
264 headache 10.0
265 somatostatinoma 10.0 VIP SST INS GHRH
266 pervasive developmental disorder 10.0 IGF1 HTR2A DRD4 DRD2
267 motor neuron disease 10.0 INS IGF1 HTR2A GH1
268 migraine with aura 10.0 VIP HTR2C HTR2A DRD2
269 acidophil adenoma 10.0 TRH SST PRL POMC INS IGF1
270 adrenal gland disease 10.0 SST PRL POMC INS IGF1 GNAS
271 neuroendocrine tumor 10.0 VIP SST POMC GHRH
272 cocaine dependence 10.0 PRL POMC HTR2C HTR2A DRD2
273 overnutrition 10.0 SHBG POMC INS IGF1
274 rett syndrome 9.9 VIP SST POMC DRD2
275 sarcoidosis 1 9.9
276 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
277 adenomyosis 9.9
278 heart disease 9.9
279 hepatic encephalopathy 9.9
280 cholestasis 9.9
281 gonadal dysgenesis 9.9
282 adenocarcinoma 9.9
283 germinoma 9.9
284 cocaine abuse 9.9
285 neurofibromatosis 9.9
286 alopecia 9.9
287 48,xyyy 9.9
288 endogenous depression 9.9 TRH PRL POMC INS HTR2A GNRH1
289 fetal macrosomia 9.9 INS IGF1 H19
290 silver-russell syndrome 1 9.9 IGF1 H19 GNAS
291 steroid inherited metabolic disorder 9.9 SHBG PRL POMC INS GNRH1
292 hypoactive sexual desire disorder 9.9 SHBG PRL HTR2C HTR2A
293 psychosexual disorder 9.9 SHBG PRL HTR2C HTR2A
294 fibrosis of extraocular muscles, congenital, 1 9.9
295 syringomyelia, noncommunicating isolated 9.9
296 cystic fibrosis 9.9
297 spondylometaphyseal dysplasia, sedaghatian type 9.9
298 helicobacter pylori infection 9.9
299 nasopharyngeal carcinoma 9.9
300 coronary heart disease 1 9.9
301 chikungunya 9.9
302 exanthem 9.9
303 bone disease 9.9
304 gastric ulcer 9.9
305 opioid abuse 9.9
306 constrictive pericarditis 9.9
307 cardiovascular system disease 9.9
308 brain cancer 9.9
309 pedophilia 9.9
310 pulmonary valve insufficiency 9.9
311 perivascular epithelioid cell tumor 9.9
312 astrocytoma 9.9
313 syringomyelia 9.9
314 myopathy 9.9
315 movement disease 9.9
316 aortic valve insufficiency 9.9
317 congestive heart failure 9.9
318 peptic ulcer disease 9.9
319 placenta disease 9.9
320 47,xyy 9.9
321 cutis verticis gyrata 9.9
322 granulomatous hypophysitis 9.9
323 disorder of copper metabolism 9.9
324 functioning gonadotropic adenoma 9.9
325 hormone producing pituitary cancer 9.8 SST PRL POMC IGF1 GNAS GHRH
326 atrial standstill 1 9.8
327 hyperthyroxinemia, dystransthyretinemic 9.8
328 optic nerve hypoplasia, bilateral 9.8
329 prostate cancer 9.8
330 dowling-degos disease 1 9.8
331 rheumatoid arthritis 9.8
332 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.8
333 myxedema 9.8
334 sjogren syndrome 9.8
335 prostatic hyperplasia, benign 9.8
336 spermatogenic failure 3 9.8
337 psoriatic arthritis 9.8
338 bone mineral density quantitative trait locus 8 9.8
339 premature ovarian failure 7 9.8
340 bone mineral density quantitative trait locus 15 9.8
341 peripartum cardiomyopathy 9.8
342 lymphoma 9.8
343 breast abscess 9.8
344 familial glucocorticoid deficiency 9.8
345 lactocele 9.8
346 prostatic hypertrophy 9.8
347 paranoid schizophrenia 9.8
348 graves' disease 9.8
349 secondary hyperparathyroidism 9.8
350 hepatic coma 9.8
351 leiomyoma 9.8
352 uveitis 9.8
353 diarrhea 9.8
354 hyperparathyroidism 9.8
355 premature ejaculation 9.8
356 papilloma 9.8
357 cystic teratoma 9.8
358 hyperthyroxinemia 9.8
359 prostatic adenoma 9.8
360 mammary paget's disease 9.8
361 liver disease 9.8
362 urinary tract obstruction 9.8
363 chronic kidney disease 9.8
364 arthritis 9.8
365 vasculitis 9.8
366 intracranial hypertension 9.8
367 fatty liver disease 9.8
368 head injury 9.8
369 idiopathic central precocious puberty 9.8
370 peripheral hypothyroidism 9.8
371 pik3ca-related overgrowth syndrome 9.8
372 carney complex variant 9.8 SST PRL POMC IGF1 GNAS GHRH
373 specific developmental disorder 9.8 POMC INS IGF1 HTR2A DRD4 DRD2
374 pseudohypoparathyroidism, type ia 9.8 TRH PTHLH PRL IGF1 GNAS GHRH
375 sebaceous gland disease 9.7 SHBG PRL POMC INS IGF1 GNRH1
376 disorders of sexual development 9.7 SHBG PRL POMC INS IGF1 GNRH1
377 premature ovarian failure 1 9.7 SHBG PRL POMC INS IGF1 GNRH1
378 cryptorchidism, unilateral or bilateral 9.7 SHBG PRL POMC INS IGF1 GNRH1
379 endocrine organ benign neoplasm 9.7 TRH SST PRL POMC IGF1 GNAS
380 beckwith-wiedemann syndrome 9.7 INS IGF1 H19 GNAS
381 spondyloarthropathy 1 9.7
382 atherosclerosis susceptibility 9.7
383 alopecia, androgenetic, 1 9.7
384 gastroesophageal reflux 9.7
385 colorectal cancer 9.7
386 cardiofaciocutaneous syndrome 1 9.7
387 carpal tunnel syndrome 9.7
388 gilles de la tourette syndrome 9.7
389 renal cell carcinoma, nonpapillary 9.7
390 hypertelorism 9.7
391 hypertriglyceridemia, familial 9.7
392 meniere disease 9.7
393 myelopathy, htlv-1-associated 9.7
394 noonan syndrome 1 9.7
395 teratoma, ovarian 9.7
396 parkinson disease, late-onset 9.7
397 pemphigus vulgaris, familial 9.7
398 multiple endocrine neoplasia, type iia 9.7
399 porphyria, acute intermittent 9.7
400 scleroderma, familial progressive 9.7
401 temporal arteritis 9.7
402 thyroid cancer, nonmedullary, 1 9.7
403 suppressor of tumorigenicity 3 9.7
404 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
405 celiac disease 1 9.7
406 chordoma 9.7
407 costello syndrome 9.7
408 lymphoma, hodgkin, classic 9.7
409 hypoadrenocorticism, familial 9.7
410 hypogonadism, male 9.7
411 prolactin deficiency, isolated 9.7
412 smith-lemli-opitz syndrome 9.7
413 mayer-rokitansky-kuster-hauser syndrome 9.7
414 opitz gbbb syndrome, type i 9.7
415 androgen insensitivity syndrome 9.7
416 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.7
417 mental retardation, skeletal dysplasia, and abducens palsy 9.7
418 aging 9.7
419 oncocytoma 9.7
420 leukemia, acute myeloid 9.7
421 yemenite deaf-blind hypopigmentation syndrome 9.7
422 xanthomatosis 9.7
423 cervical cancer 9.7
424 langerhans cell histiocytosis 9.7
425 lymphoma, non-hodgkin, familial 9.7
426 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
427 polysubstance abuse 9.7
428 body mass index quantitative trait locus 1 9.7
429 resting heart rate, variation in 9.7
430 endometrial cancer 9.7
431 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 9.7
432 graft-versus-host disease 9.7
433 leukemia, acute lymphoblastic 3 9.7
434 multiple fibroadenomas of the breast 9.7
435 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
436 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.7
437 deficiency anemia 9.7
438 pulmonary hypertension 9.7
439 asperger syndrome 9.7
440 adult t-cell leukemia 9.7
441 diffuse large b-cell lymphoma 9.7
442 adrenal cortical adenoma 9.7
443 withdrawal disorder 9.7
444 autoimmune disease of central nervous system 9.7
445 physical disorder 9.7
446 endometrial hyperplasia 9.7
447 benign teratoma 9.7
448 familial episodic pain syndrome 9.7
449 dermatomyositis 9.7
450 portal hypertension 9.7
451 intracranial aneurysm 9.7
452 mitral valve insufficiency 9.7
453 gestational diabetes 9.7
454 allergic hypersensitivity disease 9.7
455 inflammatory spondylopathy 9.7
456 dysthymic disorder 9.7
457 low compliance bladder 9.7
458 primary biliary cirrhosis 9.7
459 dysentery 9.7
460 blastomycosis 9.7
461 guillain-barre syndrome 9.7
462 dilated cardiomyopathy 9.7
463 porphyria 9.7
464 urethritis 9.7
465 polyneuropathy 9.7
466 squamous cell papilloma 9.7
467 poems syndrome 9.7
468 renal tubular acidosis 9.7
469 prostatitis 9.7
470 avoidant personality disorder 9.7
471 keratosis 9.7
472 intraductal papilloma 9.7
473 pericarditis 9.7
474 epilepsy 9.7
475 malignant fibrous histiocytoma 9.7
476 telogen effluvium 9.7
477 encephalomalacia 9.7
478 relapsing-remitting multiple sclerosis 9.7
479 testicular disease 9.7
480 hemangioma 9.7
481 adenomyoma 9.7
482 myoma 9.7
483 dermatitis 9.7
484 endometrial adenocarcinoma 9.7
485 newcastle disease 9.7
486 breast ductal carcinoma 9.7
487 glioblastoma multiforme 9.7
488 interstitial lung disease 9.7
489 acute porphyria 9.7
490 cutis laxa 9.7
491 tropical spastic paraparesis 9.7
492 teratoma 9.7
493 central nervous system disease 9.7
494 angiomyolipoma 9.7
495 purpura 9.7
496 temporal lobe epilepsy 9.7
497 histiocytosis 9.7
498 mixed connective tissue disease 9.7
499 cranial nerve palsy 9.7
500 tricuspid valve insufficiency 9.7
501 systemic scleroderma 9.7
502 hypertrichosis 9.7
503 myofibroma 9.7
504 fibrous histiocytoma 9.7
505 hypokalemia 9.7
506 intracranial hypotension 9.7
507 cavernous hemangioma 9.7
508 benign ependymoma 9.7
509 neurotic disorder 9.7
510 atypical polypoid adenomyoma 9.7
511 ovarian cystic teratoma 9.7
512 chronic inflammatory demyelinating polyradiculoneuropathy 9.7
513 demyelinating polyneuropathy 9.7
514 mixed cell adenoma 9.7
515 cellular ependymoma 9.7
516 mature teratoma 9.7
517 ovarian germ cell teratoma 9.7
518 t-cell adult acute lymphocytic leukemia 9.7
519 juvenile type testicular granulosa cell tumor 9.7
520 acute stress disorder 9.7
521 lymphopenia 9.7
522 conjunctivitis 9.7
523 reactive arthritis 9.7
524 inflammatory breast carcinoma 9.7
525 connective tissue disease 9.7
526 spondylitis 9.7
527 b-cell lymphoma 9.7
528 t-cell lymphoblastic leukemia/lymphoma 9.7
529 subacute thyroiditis 9.7
530 meningothelial meningioma 9.7
531 subareolar duct papillomatosis 9.7
532 myocarditis 9.7
533 peritonitis 9.7
534 cataract 9.7
535 lung disease 9.7
536 nervous system disease 9.7
537 myeloid leukemia 9.7
538 pemphigus 9.7
539 central sleep apnea 9.7
540 priapism 9.7
541 iridocyclitis 9.7
542 acute myocardial infarction 9.7
543 benign mammary dysplasia 9.7
544 toxoplasmosis 9.7
545 hypereosinophilic syndrome 9.7
546 tetrahydrobiopterin deficiency 9.7
547 aip familial isolated pituitary adenomas 9.7
548 acute graft versus host disease 9.7
549 chronic thromboembolic pulmonary hypertension 9.7
550 cytokine deficiency 9.7
551 fibrosing mediastinitis 9.7
552 granulosa cell tumor of the ovary 9.7
553 htlv-1 associated myelopathy/tropical spastic paraparesis 9.7
554 leukemia, t-cell, chronic 9.7
555 pityriasis rotunda 9.7
556 polymyositis 9.7
557 pseudo-turner syndrome 9.7
558 spastic paraparesis 9.7
559 wallerian degeneration 9.7
560 autoimmune addison disease 9.7
561 autonomic dysfunction 9.7
562 brain injury 9.7
563 seizure disorder 9.7
564 spinal cord injury 9.7
565 posttransplant acute limbic encephalitis 9.7
566 adrenogenital syndrome 9.7
567 spontaneous intracranial hypotension 9.7
568 primary hypophysitis 9.7
569 acute adrenal insufficiency 9.7
570 overgrowth syndrome 9.7
571 rare cause of hypertension 9.7
572 primary adrenal insufficiency 9.7
573 thyroid carcinoma 9.7
574 attention deficit-hyperactivity disorder 9.7 PRL HTR2C HTR2A DRD4 DRD2
575 pituitary infarct 9.7 TRH SST PRL POMC INS IGF1
576 sleep disorder 9.6 PRL POMC INS IGF1 HTR2C HTR2A
577 diabetes mellitus, type i 9.6 TRH SST POMC INS IGF1 GHRH
578 bulimia nervosa 9.6 PRL POMC INS HTR2C HTR2A DRD4
579 islet cell tumor 9.5 VIP SST PTHLH INS IGF1 GHRH
580 turner syndrome 9.5 SHBG PRL POMC INS IGF1 GHRH
581 gastric adenocarcinoma 9.4 VIP SST IGF1 H19 GNAS
582 obsessive-compulsive disorder 9.4 SST PRL POMC IGF1 HTR2C HTR2A
583 hyperpituitarism 9.4 TRH SST PRL POMC INS IGF1
584 pheochromocytoma 9.3 VIP SST PRL POMC IGF1 H19
585 thyroid gland cancer 9.1 SST POMC H19 GNAS

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Human phenotypes related to Hyperprolactinemia:

58 31 (showing 11, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 galactorrhea 58 31 occasional (7.5%) Very frequent (99-80%) HP:0100829
2 oligomenorrhea 58 31 occasional (7.5%) Very frequent (99-80%) HP:0000876
3 infertility 58 31 occasional (7.5%) Frequent (79-30%) HP:0000789
4 amenorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0000141
5 hemorrhagic ovarian cyst 58 31 frequent (33%) Frequent (79-30%) HP:0012886
6 osteopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000938
7 osteoporosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000939
8 menorrhagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000132
9 female hypogonadism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000134
10 agalactia 31 very rare (1%) HP:0031109
11 increased circulating prolactin concentration 31 HP:0000870

Symptoms via clinical synopsis from OMIM:

56
Genitourinary Internal Genitalia Female:
infertility (in some patients)
oligomenorrhea (in some patients)
menorrhagia (in some patients)

Chest Breasts:
galactorrhea (in some patients)
agalactia (in some patients)

Endocrine Features:
elevated prolactin levels

Clinical features from OMIM:

615555

MGI Mouse Phenotypes related to Hyperprolactinemia:

45 (showing 13, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 DRD2 DRD4 GAL GHRH GNAS HTR2A
2 homeostasis/metabolism MP:0005376 10.36 DRD2 DRD4 GAL GHRH GNAS GNRH1
3 endocrine/exocrine gland MP:0005379 10.34 DRD2 GAL GHRH GNAS GNRH1 HTR2A
4 growth/size/body region MP:0005378 10.29 DRD2 GAL GHRH GNAS GNRH1 HTR2C
5 immune system MP:0005387 10.21 DRD2 GHRH GNAS GNRH1 HTR2C IGF1
6 adipose tissue MP:0005375 10.18 DRD2 GHRH GNAS HTR2C IGF1 INS
7 integument MP:0010771 10.14 DRD2 GAL GNAS GNRH1 HTR2C IGF1
8 nervous system MP:0003631 10.13 DRD2 DRD4 GAL GHRH GNAS GNRH1
9 liver/biliary system MP:0005370 9.97 DRD2 GHRH GNAS GNRH1 INS POMC
10 neoplasm MP:0002006 9.92 DRD2 GNAS GNRH1 IGF1 POMC PRL
11 renal/urinary system MP:0005367 9.76 DRD2 GNAS GNRH1 IGF1 INS POMC
12 reproductive system MP:0005389 9.65 DRD2 GAL GHRH GNRH1 IGF1 INS
13 skeleton MP:0005390 9.36 DRD2 GHRH GNAS GNRH1 HTR2A IGF1

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 135, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
4
Ziprasidone Approved Phase 4 146939-27-7 60854
5
Clozapine Approved Phase 4 5786-21-0 2818
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Amantadine Approved Phase 4 768-94-5 2130
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
13 Insulin, Globin Zinc Phase 4
14 insulin Phase 4
15 Anti-Obesity Agents Phase 4
16 Lipid Regulating Agents Phase 4
17 Appetite Depressants Phase 4
18 Dopamine agonists Phase 4
19 Serotonin 5-HT1 Receptor Agonists Phase 4
20 Serotonin Receptor Agonists Phase 4
21 Trace Elements Phase 4
22 Micronutrients Phase 4
23 Vitamins Phase 4
24 Nutrients Phase 4
25 Calciferol Phase 4
26 Calcium, Dietary Phase 4
27 Mitogens Phase 4
28 Endothelial Growth Factors Phase 4
29 Paliperidone Palmitate Phase 4
30 Angiogenesis Inducing Agents Phase 4
31 Antipsychotic Agents Phase 4
32 Dopamine Agents Phase 4
33 Dopamine Antagonists Phase 4
34 Antidepressive Agents Phase 4
35 Psychotropic Drugs Phase 4
36 Hormones Phase 4
37 Antiparkinson Agents Phase 4
38 Anti-Infective Agents Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Antiviral Agents Phase 4
41 Quetiapine Fumarate Phase 4 111974-72-2
42 Estradiol 17 beta-cypionate Phase 4
43 Estradiol 3-benzoate Phase 4
44
Calcium Nutraceutical Phase 4 7440-70-2 271
45
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
46
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
47
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
48
Metformin Approved Phase 3 657-24-9 14219 4091
49
Cyproterone Acetate Approved, Investigational Phase 2, Phase 3 427-51-0
50
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
51
Calcium carbonate Approved, Investigational Phase 3 471-34-1
52
Sodium citrate Approved, Investigational Phase 3 68-04-2
53
Brexpiprazole Approved, Investigational Phase 3 913611-97-9 11978813
54
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
55
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
56
Enclomiphene Investigational Phase 3 15690-57-0
57 Contraceptives, Oral, Combined Phase 2, Phase 3
58 Contraceptives, Oral Phase 2, Phase 3
59
Cyproterone Phase 2, Phase 3 2098-66-0 5284537
60 Hormone Antagonists Phase 3
61 Pharmaceutical Solutions Phase 2, Phase 3
62 Citrate Phase 3
63 Estrogen Receptor Antagonists Phase 3
64 Estrogen Antagonists Phase 3
65 Estrogen Receptor Modulators Phase 3
66 Clomiphene Phase 3
67 Estrogens Phase 3
68 Zuclomiphene Phase 3
69 Anesthetics Phase 2, Phase 3
70 Raloxifene Hydrochloride Phase 3
71 Aromatase Inhibitors Phase 3
72 Progestins Phase 2, Phase 3
73
Cabergoline Approved Phase 1, Phase 2 81409-90-7 54746
74
Licorice Approved Phase 2
75
Exenatide Approved, Investigational Phase 2 141758-74-9 15991534
76
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
77
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 497540 5095
78
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
79 Vitamin B Complex Phase 2
80 Folate Phase 2
81 Vitamin B9 Phase 2
82 Liver Extracts Phase 2
83 Hypoglycemic Agents Phase 2
84 Incretins Phase 2
85 Chelating Agents Phase 2
86 Anticoagulants Phase 2
87
Medroxyprogesterone acetate Approved, Investigational Phase 1 71-58-9
88
Olanzapine Approved, Investigational Phase 1 132539-06-1 4585
89
Haloperidol Approved Phase 1 52-86-8 3559
90
Mesoridazine Approved, Investigational Phase 1 5588-33-0 4078
91
Fluphenazine Approved Phase 1 69-23-8 3372
92
Thiothixene Approved Phase 1 3313-26-6, 5591-45-7 941651
93
Perphenazine Approved Phase 1 58-39-9 4748
94
Trifluoperazine Approved, Investigational Phase 1 117-89-5 5566
95
Loxapine Approved Phase 1 1977-10-2 3964
96
leucovorin Approved Phase 1 58-05-9 6006 143
97
Medroxyprogesterone Phase 1 520-85-4 10631
98 Haloperidol decanoate Phase 1
99
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 10204 6013
100
Levodopa Approved 59-92-7 6047
101
Bevacizumab Approved, Investigational 216974-75-3
102
Oxytocin Approved, Vet_approved 50-56-6 53477758 439302
103
Cetrorelix Approved, Investigational 120287-85-6 16129715 25074887
104
Ganirelix Approved 123246-29-7, 124904-93-4 25081094
105
Menotropins Approved 61489-71-2, 9002-68-0 5360545
106
Amisulpride Approved, Investigational 53583-79-2, 71675-85-9 2159
107
Parathyroid hormone Approved, Investigational 9002-64-6
108
Epinephrine Approved, Vet_approved 51-43-4 5816